Design strategies, SAR, and mechanistic insight of Aurora kinase inhibitors in cancer

Author:

Sankhe Kaksha1,Prabhu Arati2,Khan Tabassum2ORCID

Affiliation:

1. Department of Pharmaceutical Chemistry SVKM’s Dr. Bhanuben Nanavati College of Pharmacy Mumbai India

2. Department of Pharmaceutical Chemistry and Quality Assurance Bhanuben Nanavati College of Pharmacy Mumbai India

Publisher

Wiley

Subject

Molecular Medicine,Biochemistry,Drug Discovery,Pharmacology,Organic Chemistry

Reference78 articles.

1. A Phase 1 Dose Escalation Study of TAK‐901 in Subjects With Advanced Hematologic Malignancies ‐ Full Text View ‐ ClinicalTrials.gov.(n.d.). Retrieved June 16 2020 fromhttps://clinicaltrials.gov/ct2/show/NCT00807677?term=TAK‐901&draw=2&rank=2

2. A Study of ENMD‐2076 in Ovarian Clear Cell Cancers ‐ Full Text View ‐ ClinicalTrials.gov.(n.d.). Retrieved June 16 2020 fromhttps://clinicaltrials.gov/ct2/show/NCT01914510?term=ENMD‐2076&draw=2&rank=1

3. Discovery of GSK1070916, a Potent and Selective Inhibitor of Aurora B/C Kinase

4. Inhibition of Aurora-B kinase activity confers antitumor efficacy in preclinical mouse models of early and advanced gastrointestinal neoplasia

5. Aurora A is a prognostic marker for breast cancer arising inBRCA2mutation carriers

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3